The Defense Health Agency (DHA) awarded a $2,986,772.93 Firm Fixed Price contract to Perfusion Medical LLC, a small business biotechnology company, for IND-enabling studies of PM-208, a novel pre-hospital anti-shock therapeutic. This contract, which is part of the Small Business Innovation Research (SBIR) program Phase II, is set aside for small businesses. Perfusion Medical LLC specializes in developing innovative intravenous solutions for treating acute medical conditions such as septic shock, hemorrhagic shock, and acute kidney injury. The company has received multiple federal contract and grant awards, including a $1,799,322.00 STTR Phase II contract from the Air Force Research Laboratory for optimizing the dosing and formulation of PM-208 for Air Force field use, as well as a $75,000 SBIR Phase I award from the Air Force Research Laboratory to study the use of PEG-20K/8K in treating septic shock, hemorrhagic shock, and acute kidney injury.
Generated 8/14/24, 9:55 AM